3. ๊ท€๊ฐ€ ํŠธ์ด๋Š” ์˜์–ด

24.09.06 Novo Nordisk's $4.1 Billion Investment in Weight Loss Drug Production

ํ•˜ ๋Œ€ํ‘œ 2024. 10. 9. 04:56

Novo Nordisk has announced plans to construct a $4.1 billion' manufacturing facility โ€‹in North Carolina.

๋…ธ๋ณด๋…ธ๋””์Šคํฌ๊ฐ€ ๋…ธ์Šค์บ๋กค๋ผ์ด๋‚˜์ฃผ์— 41์–ต ๋‹ฌ๋Ÿฌ ๊ทœ๋ชจ์˜ ์ƒ์‚ฐ ์‹œ์„ค์„ ๊ฑด๋ฆฝํ•  ๊ณ„ํš์„ ๋ฐœํ‘œํ–ˆ๋‹ค.

* construct : <๊ฑด๋ฌผโˆ™๋‹ค๋ฆฌโˆ™๋„๋กœ ๋“ฑ>์„ ๊ฑด์„คํ•˜๋‹ค, ๊ฑด์ถ•ํ•˜๋‹ค

* manufacturing facility : ์ƒ์‚ฐ ์‹œ์„ค[๊ณต์žฅ]

โ€‹

This is to address the surging demand for its popular weight loss and diabetes medications.

์ž์‚ฌ ์ธ๊ธฐ ์•ฝํ’ˆ์ธ ์ฒด์ค‘ ๊ฐ๋Ÿ‰ ๋ฐ ๋‹น๋‡จ๋ณ‘ ์น˜๋ฃŒ ์•ฝ๋ฌผ์— ๋Œ€ํ•œ ์ˆ˜์š” ๊ธ‰์ฆ์„ ํ•ด๊ฒฐํ•˜๊ธฐ ์œ„ํ•œ ์กฐ์น˜์ด๋‹ค.

* address : <๋ฌธ์ œโˆ™์Ÿ์  ๋“ฑ>์„ ๋‹ค๋ฃจ๋‹ค, โ‹ฏ์— ๋Œ€์‘ํ•˜๋‹ค, ๋Œ€์ฒ˜ํ•˜๋‹ค

* surge : ๊ธ‰์ฆํ•˜๋‹ค, ๊ธ‰๋“ฑํ•˜๋‹ค

* diabetes : ๋‹น๋‡จ๋ณ‘

โ€‹

The new plant will focus on filling and packaging syringes and injection pens for drugs like Wegovy and Ozempic.

โ€‹์‹ ์„ค ๊ณต์žฅ์—์„œ๋Š” ์œ„๊ณ ๋น„์™€ ์˜ค์ ฌํ”ฝ ๋“ฑ์˜ ์•ฝ๋ฌผ์„ ์ฃผ์‚ฌ๊ธฐ ๋ฐ ์ฃผ์‚ฌ ํŽœ์— ์ฃผ์ž…ํ•˜๊ณ  ํฌ์žฅํ•˜๋Š” ์ž‘์—…์ด ์ฃผ๋กœ ์ง„ํ–‰๋  ์˜ˆ์ •์ด๋‹ค.

* syringe : ์ฃผ์‚ฌ๊ธฐ

* injection : ์ฃผ์‚ฌ

โ€‹

This expansion is part of the company's increased investment in production, which has nearly doubled from the previous year.

์ด๋ฒˆ ํ™•์žฅ์€ ์ž‘๋…„ ๋Œ€๋น„ ๋‘ ๋ฐฐ ๊ฐ€๊นŒ์ด ์ฆ๊ฐ€ํ•œ ์ƒ์‚ฐ์— ํˆฌ์ž๋ฅผ ๋Š˜๋ฆฌ๋Š” ํšŒ์‚ฌ ์ „๋žต์˜ ์ผํ™˜์ด๋‹ค.

โ€‹

The 1.4 million-square-foot facility will create 1,000 new jobs, adding to the existing workforce in the region.

140๋งŒ ์ œ๊ณฑํ”ผํŠธ ๊ทœ๋ชจ์˜ ์‹œ์„ค์€ 1,000๊ฐœ์˜ ์ƒˆ๋กœ์šด ์ผ์ž๋ฆฌ๋ฅผ ์ฐฝ์ถœํ•˜์—ฌ ํ•ด๋‹น ์ง€์—ญ์˜ ๊ธฐ์กด ๋…ธ๋™ ์ธ๊ตฌ๋ฅผ ์ฆ๊ฐ€์‹œํ‚จ๋‹ค.

* existing : ์ง€๊ธˆ ์žˆ๋Š”, ๊ธฐ์กด์˜

* workforce : (ํŠน์ • ๊ตญ๊ฐ€โˆ™์ง€์—ญ์˜) ๋…ธ๋™์ธ๊ตฌ, ๋…ธ๋™๋ ฅ

โ€‹

It joins several other Novo Nordisk production sites in North Carolina and New Hampshire, as well as international locations.

โ€‹๋…ธ์Šค์บ๋กค๋ผ์ด๋‚˜์ฃผ์™€ ๋‰ดํ–„ํ”„์…”์ฃผ์— ์œ„์น˜ํ•œ ์—ฌ๋Ÿฌ ๋‹ค๋ฅธ ๋…ธ๋ณด๋…ธ๋””์Šคํฌ ์ƒ์‚ฐ์ง€ ๋ฐ ๊ตญ์ œ ์ง€์ ์— ๋”ํ•ด์ง„๋‹ค.

โ€‹

The investment aims to alleviate shortages of certain drug doses in the U.S. market, where patient demand has been rapidly increasing.

์ด๋ฒˆ ํˆฌ์ž๋Š” ํ™˜์ž ์ˆ˜์š”๊ฐ€ ๊ธ‰์ฆํ•˜๊ณ  ์žˆ๋Š” ๋ฏธ๊ตญ ์‹œ์žฅ์—์„œ ํŠน์ • ์•ฝ๋ฌผ ๊ณต๊ธ‰๋Ÿ‰ ๋ถ€์กฑ์„ ์™„ํ™”ํ•˜๋Š” ๊ฒƒ์„ ๋ชฉํ‘œ๋กœ ํ•œ๋‹ค.

* aim to do something : โ‹ฏํ•˜๋Š” ๊ฒƒ์„ ๋ชฉํ‘œ๋กœ ํ•˜๋‹ค, โ‹ฏํ•  ์ƒ๊ฐ์ด๋‹ค

* alleviate : <๋ฌธ์ œโˆ™์œ„๊ธฐ ์ƒํ™ฉ ๋“ฑ>์„ ์™„ํ™”ํ•˜๋‹ค, <๊ณ ํ†ตโˆ™๊ดด๋กœ์›€ ๋“ฑ>์„ ๊ฒฝ๊ฐ์‹œํ‚ค๋‹ค

* shortage : ๋ถ€์กฑ

* dose : (์•ฝโˆ™์•ฝ๋ฌผ์˜) (1ํšŒ) ๋ณต์šฉ๋Ÿ‰, ํˆฌ์—ฌ๋Ÿ‰

โ€‹

This move comes as competition intensifies, with rival company Eli Lilly also expanding its manufacturing capabilities.

๊ฒฝ์Ÿ์‚ฌ์ธ ์ผ๋ผ์ด ๋ฆด๋ฆฌ๋„ ๋งˆ์ฐฌ๊ฐ€์ง€๋กœ ์ œ์กฐ ์—ญ๋Ÿ‰์„ ํ™•๋Œ€ํ•˜๋Š” ๋“ฑ ๊ฒฝ์Ÿ์ด ์‹ฌํ™”๋˜๋Š” ๊ฐ€์šด๋ฐ ๋‚˜์˜จ ์กฐ์น˜์ด๋‹ค.

* intensify : <๊ฒฝ์Ÿโˆ™์‹ธ์›€ ๋“ฑ์ด> ์น˜์—ดํ•ด์ง€๋‹ค, ๊ฒฉ๋ ฌํ•ด์ง€๋‹ค, <๊ฐ์ •โˆ™์—ด๊ธฐ ๋“ฑ์ด> ๊ฐ•๋ ฌํ•ด์ง€๋‹ค

* capability : (๊ธฐ๊ณ„โˆ™์‚ฌ๋žŒโˆ™์กฐ์ง ๋“ฑ์˜) ๋Šฅ๋ ฅ, ์žฌ๋Šฅ, ์ˆ˜์™„

โ€‹

Novo Nordisk's strategy involves carefully managing the release of lower doses to ensure continued treatment for existing patients.

โ€‹๋…ธ๋ณด๋…ธ๋””์Šคํฌ์˜ ์ „๋žต์€ ๊ธฐ์กด ํ™˜์ž๋“ค์˜ ์ง€์†์ ์ธ ์น˜๋ฃŒ๋ฅผ ๋ณด์žฅํ•˜๊ธฐ ์œ„ํ•ด ๋‚ฎ์€ ์šฉ๋Ÿ‰์˜ ์•ฝ๋ฌผ์„ ์‹ ์ค‘ํ•˜๊ฒŒ ๊ด€๋ฆฌํ•˜์—ฌ ์ถœํ•˜ํ•˜๋Š” ๊ฒƒ์ด๋‹ค.

* release : <์žก๊ณ  ์žˆ๋˜ ๋ฌผ๊ฑดโˆ™์† ๋“ฑ>์„ ๋†“๋‹ค

* ensure : <์•ˆ์ „โˆ™์„ฑ๊ณต ๋“ฑ>์„ ๋ณด์žฅํ•˜๋‹ค, ํ™•์‹คํ•˜๊ฒŒ ํ•˜๋‹ค

 

 

โ€‹์˜์–ด๋ฅผ ๋”~์ž˜ํ•˜๋ ค๋ฉด ์ฑ…์„ ๊ตฌ๋งคํ•ด์„œ ์ฆ๊ฒ๊ฒŒ~์”ฌ๋‚˜๊ฒŒ~ํ•˜์„ธ์š”~
์ˆ ์ˆ ์ˆ  ์˜์–ด๋ง~์ž˜~ํ•˜์‹œ๋Š” ์ฒœ์‚ฌ๋‹˜๐Ÿ˜‡๋“ค ๋•๋ถ„์— ํ–‰๋ณตํ•ฉ๋‹ˆ๋‹ค~~
9์›” ๊ท€ํŠธ์˜ ๊ต์žฌ ๊ตฌ๋งค์ฒ˜~~~๐Ÿ’›๐Ÿงก๐Ÿ’›~~~

 

 

์œ„ ๋งํฌ๋กœ ๊ตฌ๋งค์‹œ ์ฟ ํŒกํŒŒํŠธ๋„ˆ์Šค์˜ ์ผํ™˜์œผ๋กœ ์ด์— ๋”ฐ๋ฅธ ์ผ์ •์•ก์˜ ์ˆ˜์ˆ˜๋ฃŒ๋ฅผ ์ œ๊ณต๋ฐ›์Šต๋‹ˆ๋‹ค~~~
์ฒœ์‚ฌ๐Ÿ˜‡๋‹˜๋“ค ๋•๋ถ„์— ์ด๋ฃจ์–ด์ง„ ์ˆ˜์ต ๋„ˆ๋ฌด๋‚˜ ๊ฐ์‚ฌํ•ฉ๋‹ˆ๋‹ค~~ 
๋•๋ถ„์— ์ปดํŒจ์…˜ ์•„์ด๋“ค์„ ๋„์šธ์ˆ˜ ์žˆ์–ด์„œ ํ–‰๋ณตํ•ฉ๋‹ˆ๋‹ค~๐Ÿ’›๐Ÿงก๐Ÿ’›